Harrow (NASDAQ:HROW) Director Adrienne Graves Purchases 1,000 Shares

Harrow, Inc. (NASDAQ:HROW) Director Adrienne Graves bought 1,000 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were purchased at an average cost of $31.07 per share, with a total value of $31,070.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at $31,070. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Harrow Price Performance

Shares of HROW stock opened at $30.90 on Tuesday. The company has a current ratio of 2.48, a quick ratio of 2.30 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a twelve month low of $25.21 and a twelve month high of $54.85. The stock has a fifty day simple moving average of $36.41 and a two-hundred day simple moving average of $42.11. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -75.36 and a beta of 0.34.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The company had revenue of $44.20 million for the quarter, compared to analysts’ expectations of $52.43 million. During the same quarter last year, the company earned ($0.38) earnings per share. On average, analysts predict that Harrow, Inc. will post 0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Harrow

Hedge funds have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. acquired a new stake in Harrow in the 4th quarter worth approximately $26,000. KBC Group NV acquired a new position in Harrow during the 1st quarter valued at approximately $31,000. SBI Securities Co. Ltd. raised its holdings in shares of Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after buying an additional 846 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Harrow in the second quarter worth $48,000. Finally, State of Alaska Department of Revenue acquired a new stake in shares of Harrow during the third quarter worth $83,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HROW. Wall Street Zen downgraded shares of Harrow from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. Cantor Fitzgerald cut their price target on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Tuesday, May 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Harrow in a report on Thursday, March 19th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.43.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.